Actively Recruiting
Cognitive Decline and Underlying Mechanisms in Symptomatic Intracranial Atherosclerotic Stenosis Patients: A Multicenter Cohort Study
Led by Anhui Medical University · Updated on 2025-11-17
100
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the causes of cognitive decline in patients with symptomatic intracranial atherosclerotic stenosis (ICAS) and how different treatments might affect cognitive function in these patients. This multicenter cohort study focuses on understanding memory changes and the occurrence of cerebrovascular events in people with this condition. The study includes about 100 participants and is sponsored by Anhui Medical University. Participants are divided into two groups: those receiving endovascular therapy combined with standard medical treatment, and those receiving standard medical treatment alone without endovascular therapy. Standard medical management includes dual antiplatelet therapy with aspirin and clopidogrel for three months followed by monotherapy, high-dose statins, and treatment for hypertension. Endovascular therapy is performed when assigned, followed by the same medical management. Assessments occur at enrollment, after 3 months, and after 1 year. During the study, participants undergo neuropsychological testing to evaluate overall and specific cognitive domains using tools such as the Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE). Blood samples for biological research and multi-modal magnetic resonance imaging (MRI) scans are collected at baseline, 3 months, and 1 year. Researchers also monitor emotional states using anxiety and depression scales. The primary outcomes measured are changes in memory and ischemic cerebrovascular events over time.
CONDITIONS
Brief Title
Cognitive Decline and Underlying Mechanisms in Symptomatic Intracranial Artery Stenosis Patients: A Cohort Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 80 years
- Severe narrowing (70%-99%) of specific intracranial arteries confirmed by angiography or multiple imaging tests
- Recent transient ischemic attack (TIA) or minor stroke with mild symptoms (NIHSS score 4 or less)
- Right-handed and able to complete neuropsychological tests
- At least 14 days since cerebral infarction or TIA
- Signed informed consent
You will not qualify if you...
- Other diseases affecting cognitive function such as cerebral hemorrhage, Parkinson's disease, neurosyphilis, dementia, or brain tumors
- Right upper limb paralysis, speech difficulties, visual field problems, or vision impairments
- More than 50% narrowing of extracranial carotid or other major arteries
- Vasculitis, moyamoya disease, or stroke caused by heart problems
- History of head or neck stent placement, carotid surgery, aneurysm treatment, or other brain surgeries
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit (in-person)
Duration - 1 year
Participants undergo medical evaluations including neuropsychological tests, blood sample collection, and magnetic resonance imaging scans to assess cognitive function and cerebrovascular health.
3 visits (baseline, 3-month follow-up, and 1-year follow-up)
Trial Site Locations
Total: 1 location
1
Anhui Medical University
Hefei, Anhui, China, 230032
Actively Recruiting
Research Team
K
Kai Wang, PhD
Q
Qiang Wei, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here